Imagine living with a condition where your blood cannot clot properly. Every bump, every minor injury, every joint movement carries the risk of a bleeding episode that could cause permanent damage. For people with severe hemophilia A, that is daily reality. The current standard of care requires regular injections of clotting factor, sometimes every few days for life, at significant cost and with ongoing infection risk. Gene therapy promises to change that with a single treatment. On March 23, 2026, Belief BioMed and Grand Life Sciences announced an exclusive commercial partnership to bring that promise to hemophilia A patients across China.
The deal gives Grand Life Sciences the rights to commercialise BBM-H803, Belief BioMed’s investigational gene therapy for hemophilia A, across Mainland China, Hong Kong, Macau, and Taiwan.
What hemophilia A actually is and why current treatment falls short
Hemophilia A is a genetic disorder caused by a deficiency of Factor VIII, a protein essential for blood clotting. Without it, even minor injuries can trigger prolonged or spontaneous bleeding into joints, muscles, and soft tissue. Repeated joint bleeds cause progressive damage that leads to deformity and disability in severe cases. It is debilitating, expensive, and relentless.
In China, the prevalence rate sits between 2.73 and 3.09 cases per 100,000 people, with over 30,000 registered cases of hemophilia A. Most patients currently rely on Factor VIII replacement therapy, which requires frequent intravenous injections, carries infection exposure risks, and provides only temporary relief rather than addressing the underlying genetic cause. For patients in China, access to even this standard treatment is often inconsistent due to limited standardised diagnostic and therapeutic procedures.
The unmet need is urgent. A therapy that could provide long-term clotting factor production from a single treatment would be genuinely transformative for patients and their families.
How BBM-H803 works and why its regulatory progress matters
BBM-H803 is an adeno-associated virus based gene therapy. In plain terms, it uses a modified virus as a delivery vehicle to carry a working copy of the Factor VIII gene directly into liver cells. Once delivered, those cells begin producing the clotting factor the patient’s body cannot make naturally, ideally maintaining protective levels for years from a single intravenous administration.
The regulatory milestones behind this therapy are significant. The US FDA granted BBM-H803 Orphan Drug Designation in December 2022, a status reserved for therapies targeting rare diseases that signals the agency’s recognition of the drug’s potential importance. In July 2023, China’s National Medical Products Administration approved the Investigational New Drug application, allowing clinical trials to proceed. In October 2024, the FDA granted Rare Pediatric Disease Designation, adding another layer of regulatory support that could accelerate US approval pathways in the future.
A clinical trial has been ongoing since 2022. Belief BioMed also successfully launched China’s first approved gene therapy for the related condition Hemophilia B in 2025, demonstrating that the company can take gene therapies through development and into commercial approval in China. That track record matters enormously when evaluating the credibility of the Hemophilia A programme.
Why the Grand Life Sciences partnership is the right commercial vehicle
Developing a gene therapy is one challenge. Getting it to patients across a country as large and complex as China is an entirely different one. Grand Life Sciences brings exactly the commercial infrastructure that Belief BioMed needs.
Grand Life Sciences is a major pharmaceutical and healthcare enterprise with deep roots in blood products and haematology, making it a natural partner for a haemophilia programme. Its subsidiary Grand Shuyang has established blood product distribution reaching all provinces and municipalities across China, with sales networks covering hundreds of thousands of terminal outlets. That infrastructure, built over years of blood product commercialisation, translates directly into the relationships and logistics needed to reach haematology centres and specialist hospitals where haemophilia patients receive care.
According to the World Federation of Hemophilia, access to adequate haemophilia treatment remains severely limited in many parts of the developing world, with a significant proportion of patients in lower and middle income countries receiving no prophylactic treatment at all. China’s registered patient base represents a substantial underserved population where an effective gene therapy with strong commercial distribution could make an immediate difference.
The broader significance for China’s gene therapy sector
This partnership is not just about one drug. It is a signal about the maturation of China’s gene therapy industry. The Nature Biotechnology journal has documented China’s rapid emergence as a major force in cell and gene therapy development, with Chinese companies filing an increasing proportion of global clinical trials in this space. Regulatory frameworks have evolved significantly to support faster clinical development timelines.
Belief BioMed’s successful Hemophilia B approval in 2025 established a commercial precedent for gene therapy in China. The Hemophilia A programme now follows that path with an established commercial partner, a validated manufacturing process using the company’s serum-free suspension culture technology, and a regulatory strategy supported by both Chinese and US designations.
For patients in China with haemophilia A, the combination of Belief BioMed’s science and Grand Life Sciences’ commercial reach represents the most credible path yet toward accessing a therapy that could free them from a lifetime of injections.
Sources
- World Federation of Hemophilia — World Bleeding Disorders Registry
- Nature Biotechnology — Gene Therapy Research
- China NMPA — Drug Approval Information
- Belief BioMed — Official Press Release via PRNewswire
Editorial disclosure
This article is based on a press release issued by Belief BioMed and has been independently rewritten and editorially expanded. It covers a commercial partnership for an investigational gene therapy for haemophilia A. BBM-H803 has not been approved for marketing. This article discusses experimental therapies currently in clinical development and does not constitute medical advice. Market context is sourced from the World Federation of Hemophilia, Nature Biotechnology, and China’s NMPA. Commentary reflects the author’s own assessment. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
